ES2161955T3 - Benzofuranil-ureas sustituidas con heterociclilcarbonilo. - Google Patents

Benzofuranil-ureas sustituidas con heterociclilcarbonilo.

Info

Publication number
ES2161955T3
ES2161955T3 ES96119046T ES96119046T ES2161955T3 ES 2161955 T3 ES2161955 T3 ES 2161955T3 ES 96119046 T ES96119046 T ES 96119046T ES 96119046 T ES96119046 T ES 96119046T ES 2161955 T3 ES2161955 T3 ES 2161955T3
Authority
ES
Spain
Prior art keywords
ureas
substituted
heterociclilcarbonilo
benzofuranil
replaced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96119046T
Other languages
English (en)
Inventor
Gabriele Dr Braunlich
Mazen Dr Es-Sayed
Rudiger Dr Fischer
Burkhardt Dr Fugmann
Rolf Dr Henning
Michael Dr Sperzel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Application granted granted Critical
Publication of ES2161955T3 publication Critical patent/ES2161955T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

BENZOFURANILUREAS SUSTITUIDAS CON HETEROCICLILOCARBONILO DE FORMULA (I) SE PREPARAN MEDIANTE LA REACCION DE 3-AMINOBENZOFURANOS SUSTITUIDOS CON HETEROCICLILOCARBONILO CON ISOCIANATOS O ISOTIOCIANATOS ADECUADOS. LAS UREAS INSUSTITUIDAS SON TRANSFERIDAS EN UREAS SUSTITUIDAS MEDIANTE METODOS DE SUSTITUCION USUALES. LAS BENZOFURANILUREAS SUSTITUIDAS CON HETEROCICLILOCARBONILO SON UTILES COMO INGREDIENTES ACTIVOS EN MEDICAMENTOS PARTICULARMENTE PARA EL TRATAMIENTO DE PROCESOS INFLAMATORIOS AGUDOS Y CRONICOS. A, D, L, R{SUP,1}, R{SUP,2}, R{SUP,3}, R{SUB,4} SON COMO SE DEFINIA EN LAS APLICACIONES, R{SUP,4} SIENDO UN GRUPO HETEROCICLICO.
ES96119046T 1995-12-11 1996-11-28 Benzofuranil-ureas sustituidas con heterociclilcarbonilo. Expired - Lifetime ES2161955T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9525262.3A GB9525262D0 (en) 1995-12-11 1995-12-11 Heterocyclylcarbonyl substituted benzofuranyl-ureas

Publications (1)

Publication Number Publication Date
ES2161955T3 true ES2161955T3 (es) 2001-12-16

Family

ID=10785231

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96119046T Expired - Lifetime ES2161955T3 (es) 1995-12-11 1996-11-28 Benzofuranil-ureas sustituidas con heterociclilcarbonilo.

Country Status (10)

Country Link
US (1) US5922740A (es)
EP (1) EP0779291B1 (es)
JP (1) JPH09202785A (es)
AT (1) ATE206709T1 (es)
CA (1) CA2192281A1 (es)
DE (1) DE69615802T2 (es)
DK (1) DK0779291T3 (es)
ES (1) ES2161955T3 (es)
GB (1) GB9525262D0 (es)
PT (1) PT779291E (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
US5591776A (en) 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
GB9614718D0 (en) * 1996-07-12 1996-09-04 Bayer Ag 3-ureido-pyridofurans and -pyridothiophenes
UY25338A1 (es) * 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd
GB2350110A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofurans
GB2350112A (en) * 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active cycloalkyl ketones
GB2350109A (en) 1999-05-17 2000-11-22 Bayer Ag Pharmaceutically active benzofuranyl sulfonates
GB2350111A (en) * 1999-05-17 2000-11-22 Bayer Ag Oligohydroxyl substituted 3-urea-benzofuran and pyridofuran derivatives
DE10064997A1 (de) 2000-12-23 2002-06-27 Merck Patent Gmbh Benzoylpyridazine
DE10150517A1 (de) * 2001-10-12 2003-04-17 Merck Patent Gmbh Verwendung von Phosphodiesterase IV-Inhibitoren
US7144885B2 (en) 2002-02-22 2006-12-05 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
EP1478639A1 (en) * 2002-02-22 2004-11-24 Bayer Pharmaceuticals Corporation Fused tricyclic heterocycles useful for treating hyper-proliferative disorders
JP4206382B2 (ja) * 2002-11-19 2009-01-07 アキリオン ファーマシューティカルズ，インコーポレーテッド 置換されたアリールチオウレアおよび関連化合物；ウイルス複製のインヒビター
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
DE102005055354A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh Substituierte 5-Phenyl-3,6-dihydro-2-oxo-6H-[1,3,4]thiadiazine
DE102005055355A1 (de) * 2005-11-21 2007-10-31 Merck Patent Gmbh 3,6-Dihydro-2-oxo-6H-[1,3,4]thiadiazinderivate
CA2666469A1 (en) * 2006-09-01 2008-03-06 Bayer Healthcare Ag Benzofuran and benzothiophene derivatives useful in the treatment of cancers of the central nervous system
US8084612B2 (en) * 2008-01-08 2011-12-27 Purdue Pharma L.P. Proline analogs as ligands for cannabinoid receptors
US8883857B2 (en) 2012-12-07 2014-11-11 Baylor College Of Medicine Small molecule xanthine oxidase inhibitors and methods of use
BR112015032921B1 (pt) * 2013-07-03 2022-06-14 Karyopharm Therapeutics, Inc Compostos de benzofuranila e benzoxazolila substituídos e utilizações dos mesmos
US10822299B2 (en) 2016-05-26 2020-11-03 The Regents Of The University Of California Compounds and methods for hematopoietic regeneration
WO2019108800A1 (en) * 2017-11-29 2019-06-06 The Regents Of The University Of California Compounds and methods for hematopoietic regeneration

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4745127A (en) * 1983-10-31 1988-05-17 Merck Frosst Canada, Inc. Benzyl esters of benzofuran-2-carboxylic acids useful as inhibitors of leukotriene biosynthesis
EP0146243A1 (en) * 1983-10-31 1985-06-26 Merck Frosst Canada Inc. Lipoxygenase inhibitors
NZ237566A (en) * 1990-03-27 1994-03-25 Smithkline Beecham Corp Substituted amide and hydroxyamine derivatives and pharmaceutical compositions
JPH07267961A (ja) * 1994-03-30 1995-10-17 Taisho Pharmaceut Co Ltd ベンゾフロ［３，２−ｄピリミジン−４−オン誘導体
GB9504460D0 (en) * 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives

Also Published As

Publication number Publication date
PT779291E (pt) 2002-02-28
DK0779291T3 (da) 2002-01-21
CA2192281A1 (en) 1997-06-12
DE69615802T2 (de) 2002-04-04
EP0779291B1 (en) 2001-10-10
EP0779291A1 (en) 1997-06-18
US5922740A (en) 1999-07-13
JPH09202785A (ja) 1997-08-05
ATE206709T1 (de) 2001-10-15
DE69615802D1 (de) 2001-11-15
GB9525262D0 (en) 1996-02-07

Similar Documents

Publication Publication Date Title
ES2161955T3 (es) Benzofuranil-ureas sustituidas con heterociclilcarbonilo.
AU3707393A (en) Anticonvulsant fructopyranose cyclic sulfites and sulfates
DE3750906T2 (de) Chemisch modifizierte Proteine und deren Herstellung.
FI954874A (fi) Amino(tio)eetterijohdannaisia
ATE45942T1 (de) Diarylacetylene, ihre herstellung und verwendung.
DE69817802D1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
CA2117511A1 (en) N-cyanoaryl-nitrogen heterocycles
NO942372L (no) Propensyrederivater
MX9203548A (es) Compuestos de penem, su produccion y uso.
IE870284L (en) 5-amino-1-phenyl-pyrazole herbicides
ATE132T1 (de) Substituierte n-benzoyl-n '-tert.-alkoxycarbonylphenyl-(thio)harnstoffe, verfahren zu ihrer herstellung und ihre verwendung als insektizide.
NO975679L (no) Fremgangsmåte for fremstilling av N-monosubstituerte og N,N'-disubstituerte, usymmetriske, cykliske ureaer
ATE58532T1 (de) (2-amino-4-aryl-thiazol-5-yl)aethanol, und deren derivate mit diuretischer aktivitaet und verfahren zu deren herstellung.
DE59404557D1 (de) Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
IT1241988B (it) 2- amminotetraline-6, 7-sostituite attive come immunomodulanti e composizioni farmaceutiche che le contengono
BR9808047B1 (pt) processo para a preparação de 2-nitroguanidinas 1,3-dissubstituìdas.
ATE25247T1 (de) 4-amino-3-imidazolin-2-on und (2-methoxy-2-imino- ethyl)-harnstoff, ihre herstellung und verwendung.
MY101540A (en) Benzoylurea compounds and their production and use.
DE69511449T2 (de) Octahydro-2-Naphthalincarbonsäure-Derivate, ihre Herstellung und Verwendung
DE69711506T2 (de) Methylsulfomycin 1, Verfahren zu dessen Herstellung und Verwendung
ATE80629T1 (de) Beta-lactam-antibiotika, verfahren zu ihrer herstellung und ihre verwendung als und in arzneimitteln.
EP0251003A3 (de) Verwendung von 2-[N-2,6-Dichlorphenyl-N-allyl-amino]-imidazolin- (2) als cytoprotektives Mittel
ATE89555T1 (de) 3-substituierte 1-(2-halogen-alkoxybenzolsulfonyl)-3-heteroaryl-harnstoffe.
BR8903043A (pt) Processo para preparacao de compostos
ATE103986T1 (de) Makromolekulare complexe pflanzlichen ursprungs, ihre herstellung und verwendung als hypocholesterinaemlische verbindung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 779291

Country of ref document: ES